Biotechnology
(NABI) Nabi Biopharmaceuticals’ Vaccine Program Advances
Nabi Biopharmaceuticals (NABI) has initiated the second phase III clinical trial for NicVAX, an investigational vaccine being developed for the treatment of nicotine addiction and preventing smoking relapse. Results from the first phase III trial are expected at the end of 2010. An...
19Mar2010 | vitalstocks | 0 comments | Continued(THRX) Theravance Offers 7.5 Million Shares
Theravance (THRX) has decided to raise funds by offering 7.5 million shares. Net proceeds are expected to be utilized for general corporate purposes including research expenses and debt reduction. However, the offer will increase the number of outstanding shares by 12%. We believe...
19Mar2010 | vitalstocks | 0 comments | Continued(CYTX) Cytori Therapeutics Plans Meeting With FDA on Clinical Program for Celution System
Last week, Cytori Therapeutics (CYTX) was notified by the U.S. FDA that they will be required to conduct a clinical program prior to final approval of its Celution System. This was in-line with our expectations. Management plans to meet with the FDA in the next few months to...
18Mar2010 | vitalstocks | 0 comments | Continued(ARIA) ARIAD Pharmaceuticals Reports In-Line Quarter
ARIAD Pharmaceuticals Inc.’s (ARIA) fourth quarter fiscal 2009 net loss per share came in at 17 cents, identical to the Zacks Consensus Estimate. The year-ago loss was 24 cents. Quarterly Results ARIAD does not have any product in the market. The entire revenue comes from licensing...
18Mar2010 | vitalstocks | 0 comments | Continued(AOB) American Oriental Bioengineering Marginally Beats Earnings Expectations
American Oriental Bioengineering’s (AOB) fourth-quarter earnings per share (EPS) came in at 14 cents surpassing the Zacks Consensus Estimate of 12 cents and 10 cents reported in the year-ago period. For 2009, the company reported EPS of 53 cents, compared to last year’s 61...
18Mar2010 | vitalstocks | 0 comments | Continued(MDVN) Medivation Reports Wider Fourth Quarter Loss
Medivation Inc. (MDVN) reported dismal results in the fourth quarter of 2009 with net loss coming in at 78 cents per share, wider than the Zacks Consensus Estimate of a net loss of 57 cents and the year-ago net loss of 26 cents. Despite full year revenues increasing to $69.3...
16Mar2010 | vitalstocks | 0 comments | Continued(MNKD) MannKind Suffers Setback From FDA
MannKind Corp. (MNKD) suffered a major setback with respect to its lead product, Afrezza, inhaled insulin for treating type I and type II diabetes. The company received a complete response letter (CRL) from the US Food & Drug Administration (FDA) recently. The FDA has asked...
16Mar2010 | vitalstocks | 0 comments | Continued(AMLN) Amylin Pharmaceuticals’ Drug Approval Delayed
The US Food and Drug Administration (FDA) recently issued a complete response letter delaying the approval of Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly and Co. (LLY) and Alkermes, Inc.’s (ALKS) once weekly formulation of Byetta (exenatide). The companies are seeking to...
16Mar2010 | vitalstocks | 0 comments | Continued(OPTR) Optimer Pharmaceuticals’ Loss Narrows
Optimer Pharma’s (OPTR) fourth quarter loss per share came in at 28 cents, narrower than the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 31 cents. For 2009, the company reported a loss per share of $1.30 compared to a loss of $1.24 in 2008. Optimer...
12Mar2010 | vitalstocks | 0 comments | Continued(NABI) Nabi Biopharmaceuticals’ Earnings Reports Bests Estimates
Nabi Biopharmaceuticals (NABI) reported fourth quarter fiscal 2009 (ended Dec 26, 2009) earnings of 2 cents per share (from continuing operations). This was well above the Zacks Consensus Estimate of a loss of 11 cents. The company suffered a loss of 10 cents (from continuing...
12Mar2010 | vitalstocks | 0 comments | Continued(PDEX) Pro-Dex – Profitability Will be the Key to Success – Undervalued?
People who are familiar with the healthcare sector might have found a different phenomenon in the New Year that investors start switching their focus on companies which have cutting edge products and long-term profitability, like Heska Corp. (HSKA) and Angiotech Pharma (ANPI). HSKA...
12Mar2010 | vitalstocks | 0 comments | Continued(HGSI) Human Genome Sciences Joins Forces With Swedish To Commercialize New Drugs
Human Genome Sciences, Inc. (HGSI) and BioInvent International AB, a Swedish pharmaceutical research company, have joined forces to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by Human Genome. However, the...
12Mar2010 | vitalstocks | 0 comments | Continued(XOMA) XOMA Earnings Report Tops Consensus Estimates
XOMA Ltd. (XOMA) reported fourth-quarter fiscal 2009 earnings of one cent per share, well above the Zacks Consensus Estimate for a loss of 3 cents but below the year-ago earnings of 7 cents. The lower earnings were primarily attributable to the dip in revenues in the fourth quarter...
12Mar2010 | vitalstocks | 0 comments | Continued(MITI) Micromet Announces 10 Million Share Stock Offering
Recently, Micromet (MITI) announced a 10 million share offering of common stock. In Aug 2009, Micromet received net proceeds of about $75 million from a common stock issuance. We believe with the advancement of clinical trials, the company’s R&D costs are expected to increase...
10Mar2010 | vitalstocks | 0 comments | Continued(BIIB) Biogen Experiences Pipeline Setback
Biotech company Biogen Idec (BIIB) and Swiss pharmaceutical giant Roche recently suffered a setback with one of their pipeline candidates, ocrelizumab, due to safety related issues. Biogen and Roche announced that they have suspended treatment of rheumatoid arthritis (RA) patients...
9Mar2010 | vitalstocks | 0 comments | Continued(CRTX) Cornerstone Therapeutics’ Earnings Report Tops Consensus
Cornerstone Therapeutics Inc. (CRTX) reported fiscal fourth-quarter earnings of 20 cents per share (excluding special items), which was well above the Zacks Consensus Estimate of a loss of 4 cents. The company had earned 34 cents (excluding special items) in the year-ago quarter....
8Mar2010 | vitalstocks | 0 comments | Continued(CTIC) Cell Therapeutics Gets Good News From the FDA
In a positive development, Cell Therapeutics (CTIC) announced that the US Food and Drug Administration (FDA) has completed its inspection of the company’s manufacturing facility in Italy and found it to be compliant with all the required norms. The facility manufactures Cell...
8Mar2010 | vitalstocks | 0 comments | Continued(NLTX) Nile Therapeutics Pushing Forward with CD-NP
On March 3, 2010, Nile Therapeutics (NLTX) reported financial results for the fourth quarter and full year 2009. Nile reported no revenues for the fourth quarter or full year 2009. Net loss for the fourth quarter totaled $1.6 million, or $0.06 per diluted share. For the full-year...
8Mar2010 | vitalstocks | 0 comments | Continued(MITI) Micromet’s Fourth Quarter Loss Greater Than Expectations
Micromet’s (MITI) fourth quarter loss per share came in at 34 cents, wider than the Zacks Consensus Estimate of 18 cents and a loss of 12 cents reported in the prior-year period. For 2009, the company reported a loss per share of 98 cents compared to a loss of 77 cents in 2008. Micromet...
5Mar2010 | vitalstocks | 0 comments | Continued(GILD) Gilead Sciences Shows Uptrend in Earnings Estimates
Earnings estimates for Gilead Sciences (GILD) are on the rise following the release of strong fourth quarter and full year 2009 results. The company’s earnings per share (EPS) came in at 90 cents, well above the Zacks Consensus Estimate of 82 cents and the year ago quarter’s...
5Mar2010 | vitalstocks | 0 comments | Continued(MDVN) Medivation Shares Fall on Alzheimer’s Phase III Data
Medivation, Inc. (MDVN) shares fell 67% following the release of disappointing phase III results on lead pipeline candidate dimebon. The company, along with partner Pfizer, Inc. (PFE), suffered a huge setback when dimebon failed to achieve both its primary and secondary endpoints...
4Mar2010 | vitalstocks | 0 comments | Continued(OSIR) Osiris Therapeutics Misses Estimates
Osiris Therapeutics (OSIR) reported a net loss of a cent in the fourth quarter of 2009, well below the Zacks Consensus Estimate of a net income of 23 cents per share. However, net loss in the year ago period was higher at 37 cents, mainly due to lower revenues and higher clinical...
3Mar2010 | vitalstocks | 0 comments | Continued(PDLI) PDL BioPharma’s Fourth Quarter Falls Short
PDL BioPharma, Inc. (PDLI) reported fourth-quarter fiscal 2009 earnings of 17 cents per share, 2 cents below the Zacks Consensus Estimate. The company earned 34 cents (from continuing operations) in the year-ago quarter. Results in the quarter were hurt by lower revenues. Quarterly...
3Mar2010 | vitalstocks | 0 comments | Continued(HGSI) Human Genome Sciences Reports Lower Fourth Quarter Loss
Human Genome Sciences, Inc. (HGSI) reported fourth quarter 2009 net loss of $9.7 million or 6 cents per share, narrower than the Zacks Consensus Estimate of 9 cents and the year-ago loss of $61.9 million or 46 cents. The reduced net loss for the quarter was primarily attributable...
3Mar2010 | vitalstocks | 0 comments | Continued(GILD) Gilead Sciences Earns FDA Approval for Cayston Drug
In a positive development, Gilead Sciences (GILD) received long-awaited US Food and Drug Administration (FDA) approval for Cayston (aztreonam for inhalation solution). The drug is indicated for the treatment of lung infection caused by Pseudomonas aeruginosa (P. aeruginosa)...
1Mar2010 | vitalstocks | 0 comments | Continued(AMLN) Amylin Pharmaceuticals’ Obesity Drug Pipeline Advances
Amylin Pharmaceuticals, Inc. (AMLN) and partner Takeda Pharmaceutical Company Limited recently announced that they intend to advance their obesity combination treatment of pramlintide and metreleptin into phase III studies. The decision is based on encouraging 52-week results...
25Feb2010 | vitalstocks | 0 comments | Continued(HGSI) Human Genome Sciences Pipeline Bigger than Earnings
Human Genome Sciences, Inc. (HGSI) is expected to report fourth quarter as well as fiscal 2009 results shortly. We expect that the company will report a loss of 10 cents per share for the fourth quarter of 2009 and 4 cents for fiscal 2009. However, we believe that the earnings...
25Feb2010 | vitalstocks | 0 comments | Continued(BMRN) BioMarin Pharmaceutical’s Earnings Top Analyst Estimates
BioMarin Pharmaceutical Inc. (BMRN) reported fourth-quarter 2009 earnings of 13 cents per share (excluding special items), beating the Zacks Consensus Estimate of break-even earnings. The company had earned 8 cents (excluding special items) in the year-ago quarter. Quarterly...
24Feb2010 | vitalstocks | 0 comments | Continued(ONXX) Onyx Pharmaceuticals Reports Higher Revenues
Onyx Pharmaceuticals (ONXX) has reported a fourth quarter loss of 9 cents per share, much better than a loss of 53 cents reported in the year-ago period. However, after adjusting non recurring items and treating stock-based compensation as a regular expense, the company reported...
24Feb2010 | vitalstocks | 0 comments | Continued(AMGN) Amgen Awaits US Food and Drug Administration Action on Osteoporosis Drug Candidate
The US Food and Drug Administration (FDA) recently accepted Amgen, Inc.’s (AMGN) complete response submission for Prolia, the company’s lead pipeline candidate, and established an action date of Jul 25, 2010. Amgen is seeking approval for the use of Prolia (denosumab) for...
24Feb2010 | vitalstocks | 0 comments | Continued